1. In Vivo
  2. >>Archive

The J&J Lesson

 
• By Ken West, Jim Woodward, and Reinhard Merz

J&J's exit from the coronary angioplasty market was a sign of the end of an era. Without a product at the high end of innovation, it was left with a basic product that in the interim had become commoditized.

The first challenge to Johnson & Johnson’s coronary angioplasty business came from Guidant Corp.’s introduction of a stent with greater flexibility and an improved delivery balloon catheter. The results were stunning: Guidant captured a 70% market share within 45 days of launch and by the end of 1996, the J&J market share had dropped from 91% to 8%.

Market consolidation was moving at a rapid pace. Boston Scientific Corp. had bought SciMed Life Systems Inc. in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

Deals In Depth: August 2025

 
• By Deanna Kamienski and Maureen Riordan

Seven $1bn+ alliances were penned in August, and two exceeded $2bn.

As Pricing Pressures Mount, Biopharma Turns To AI To Reduce Trial Failure Rates

 
• By David Wild

With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.